IGC Pharma, Inc. (IGC)
- Previous Close
0.3541 - Open
0.3820 - Bid 0.3873 x 1200
- Ask 0.4080 x 1800
- Day's Range
0.3800 - 0.4800 - 52 Week Range
0.2500 - 0.9100 - Volume
5,826,938 - Avg. Volume
288,306 - Market Cap (intraday)
32.289M - Beta (5Y Monthly) 1.27
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2100 - Earnings Date Nov 7, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.63
IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.
igcpharma.comRecent News: IGC
View More
Performance Overview: IGC
Trailing total returns as of 9/30/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IGC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IGC
View MoreValuation Measures
Market Cap
26.78M
Enterprise Value
25.30M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
21.26
Price/Book (mrq)
3.40
Enterprise Value/Revenue
23.82
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-47.82%
Return on Equity (ttm)
-126.20%
Revenue (ttm)
1.06M
Net Income Avi to Common (ttm)
-13.3M
Diluted EPS (ttm)
-0.2100
Balance Sheet and Cash Flow
Total Cash (mrq)
1.82M
Total Debt/Equity (mrq)
4.29%
Levered Free Cash Flow (ttm)
-3.51M
Research Analysis: IGC
View MoreCompany Insights: IGC
IGC does not have Company Insights